Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 1131 to 1140 of 1144 total matches.
Management of Opioid Withdrawal Symptoms
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018 (Issue 1554)
or baclofen.
NONPHARMACOLOGIC — Limited data suggest that
combining pharmacologic withdrawal management ...
Pharmacologic management of opioid withdrawal
symptoms can reduce the intensity of drug craving
and improve treatment retention in patients with opioid
use disorder who will receive maintenance treatment.
Withdrawal management without subsequent maintenance
treatment is associated with high rates of
relapse, overdose death, and HIV and/or hepatitis C
virus infection. Several guidelines on management
of opioid withdrawal are available. Maintenance
treatment of opioid use disorder was reviewed in a
previous issue.
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020 (Issue 1593)
be avoided.
PREGNANCY AND LACTATION — No data on the
use of lasmiditan in pregnant or lactating women ...
Lasmiditan (Reyvow – Lilly), an oral serotonin
(5-HT1F) receptor agonist, and ubrogepant (Ubrelvy –
Allergan), an oral calcitonin gene-related peptide
(CGRP) receptor antagonist, have been approved
by the FDA for acute treatment of migraine with or
without aura in adults.
Drugs for Benign Prostatic Hyperplasia
The Medical Letter on Drugs and Therapeutics • May 02, 2022 (Issue 1649)
, depression,
and suicidality, but data supporting these associations
are generally mixed and unconvincing.17 ...
About 60% of men ≥60 years old have clinically
relevant prostatic enlargement due to benign prostatic
hyperplasia (BPH). The goals of treatment are to
decrease lower urinary tract symptoms and to prevent
disease progression and complications such as acute
urinary retention. The American Urologic Association's
guidelines for treatment of BPH were recently updated.
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
in postmenopausal women, but well-established
safety and efficacy data are lacking.2,31
Phytoestrogens ...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 doi:10.58347/tml.2024.1697a | Show Introduction Hide Introduction
Drugs for Smoking Cessation
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
developmental outcomes .50
Available human data on bupropion and varenicline
use during pregnancy do ...
Smoking tobacco remains the primary preventable
cause of death in the US. Smoking cessation often requires
both pharmacotherapy and behavioral support.
Chemotherapy for Esophageal, Gastric and Colorectal Cancers
Treatment Guidelines from The Medical Letter • Aug 01, 2006 (Issue 48)
intravenous 5-fluorouracil and
leucovorin: integrated efficacy data and novel analyses from two large ...
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
Drugs for Dementia
The Medical Letter on Drugs and Therapeutics • Mar 30, 2026 (Issue 1751)
No data are available on their safety
or efficacy for moderate or severe AD dementia. Both
drugs reduce ...
Alzheimer's disease (AD) is the most common cause
of dementia, but cognitive decline also occurs in
other neurological conditions, such as Parkinson's
disease, Lewy body dementia, vascular dementia, and
frontotemporal dementia.
Med Lett Drugs Ther. 2026 Mar 30;68(1751):49-56 doi:10.58347/tml.2026.1751a | Show Introduction Hide Introduction
Drugs for Cardiac Arrhythmias
Treatment Guidelines from The Medical Letter • Jun 01, 2007 (Issue 58)
infarction and in congestive heart failure: meta-analysis of individual data from 6500
patients ...
The drugs of choice for treatment of common cardiac arrhythmias are listed in Tables 1 and 2. Some drugs are recommended for indications that have not been approved by the FDA.
Cancer Screening
Treatment Guidelines from The Medical Letter • Dec 01, 2012 (Issue 124)
,
generates a 2- or 3-dimensional colorectal image using
data input from a helical (spiral) CT scan ...
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may
improve outcomes. Screening tests for some common
cancers are reviewed below.
Vaccines for Travelers
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018 (Issue 1560)
of worldwide prevalence of
chronic hepatitis B virus infection: a systematic review of data
published between ...
Persons planning to travel outside the US should be
up to date on routine vaccines and, depending on their
destination, duration of travel, and planned activities,
may also receive certain travel-specific vaccines.
Tickborne encephalitis and dengue vaccines, which
are not available in the US, are reviewed in a separate
article available online. Detailed advice for travel to
specific destinations is available from the Centers for
Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for
administration of vaccines as part of routine...
